Keryx Biopharmaceuticals: "We don't care where a stock has come from, we care where it is going to. This happens to be a stock I have to tell you that I think does have great speculative capabilities. I'm going to say stick with it. I don't want to buy more here because it's had a move, but I do like it because I happen to like the ones that are working on renal that are doing so well in phase three."
Rodman and Renshaw analyst's comments:
Several companies have begun developing a vaccine to fight the Zika virus, but Selvaraju believes there are several factors that indicate Inovio has the ability to produce a more effective drug in a swifter manner than its competitors. First, Inovio has sufficient capital to finish the study quickly. The analyst expects Phase 2 trials to begin as soon as 2017. Furthermore, when Inovio did preclinical studies the drug caused “robust antibody and T cell responses in both small and large animal models.” Lastly, Inovio’s DNA vaccine design platform technology, SynCon, allows Inovio to produce vaccines faster than other companies which was evident in its development of its Ebola and MERS vaccines. Thanks to these advantages, the analyst remains confident that Inovio will remain at the forefront of the race to fight Zika.
Following these updates, the analyst reiterates his Buy rating on Inovio with a price target of $17, marking a 49% increase from current levels.
Sentiment: Strong Buy
Good stuff, though as far as I'm concerned you can double their price target....
Maxim affirmed Inovio Pharmaceuticals (Nasdaq: INO) with a Buy rating and $14 price target as Inovio announced that its immunotherapy for hepatitis C (INO-8000) will be evaluated in a phase I trial in chronically infected patients who are not receiving other hepatitis C virus (HCV) treatments.
Analyst Jason McCarthy commented on the news: While the HCV space has been dominated by blockbuster antivirals like Harvoni and Sovaldi that are essentially a cure, their high cost is and will likely remain a factor that limits access to many patients. A more cost effective alternative (or in addition to antiviral therapy) would be a vaccine approach like INO-8000, which beyond initial viral elimination would also induce immune memory, potentially guarding against re-infection.
Co announced positive data from its OpsiSporin programme, a sustained release treatment with Q-Cyclosporin for the treatment of non-infective uveitis.
In a recent study to evaluate the efficacy of MTD202 in a preclinical model of Experimental Autoimmune Uveitis, a strong dose response profile was demonstrated at 15ug, 50ug and 150ug per eye.
The drug is delivered intravitreal at 1000-fold lower doses than oral cyclosporine and a formal Investigational New Drug enabling and toxicology program is now being finalised prior to an expected IND submission in the second half of 2017.
Sentiment: Strong Buy
Nowhere near enough. $50 minimum
Are you a teenager? You write like a rather petulant one, so I will from now on ignore you. Bye bye.